威勝控股(03393.HK)倆附屬奪得合計2.61億元國家電網招標合約
格隆匯11月28日丨威勝控股(03393.HK)宣佈,於2024年11月26日,國家電網公佈2024年第三次計量設備招標結果,其中公司附屬公司威勝集團有限公司奪得約662,000台智能電錶的合約,合約價值約為人民幣1.7515億元(約1.8802億港元)。此外,公司的附屬公司威勝信息技術股份有限公司亦奪得約48,000台數據採集終端和集中器的合約,合約價值約為人民幣8592萬元(約9224萬港元)。
公司在本次招標取得的數量和合同總額名列前茅。截至公吿刊發日期,公司於2024年內已奪得國家電網集中招標累計價值約人民幣8.1505億元(約8.8189億港元)的合約。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.